Literature DB >> 21325652

Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes.

R J Caselli1, A C Dueck, D E C Locke, M N Sabbagh, G L Ahern, S Z Rapcsak, L C Baxter, R Yaari, B K Woodruff, C Hoffman-Snyder, R Rademakers, S Findley, E M Reiman.   

Abstract

OBJECTIVE: To characterize the effects of cerebrovascular (CV) risk factors on preclinical memory decline in cognitively normal individuals at 3 levels of genetic risk for Alzheimer disease (AD) based on APOE genotype.
METHODS: We performed longitudinal neuropsychological testing on an APOE ε4 enriched cohort, ages 21-97. The long-term memory (LTM) score of the Auditory Verbal Learning Test (AVLT) was the primary outcome measure. Any of 4 CV risk factors (CVany), including hypercholesterolemia (CHOL), prior cigarette use (CIG), diabetes mellitus (DM), and hypertension (HTN), was treated as a dichotomized variable. We estimated the longitudinal effect of age using statistical models that simultaneously modeled the cross-sectional and longitudinal effects of age on AVLT LTM by APOE genotype, CVany, and the interaction between the two.
RESULTS: A total of 74 APOE ε4 homozygotes (HMZ), 239 ε4 heterozygotes (HTZ), and 494 ε4 noncarriers were included. APOE ε4 carrier status showed a significant quadratic effect with age-related LTM decline in all models as previously reported. CVany was associated with further longitudinal AVLT LTM decline in APOE ε4 carriers (p=0.02), but had no effect in noncarriers. When ε4 HTZ and HMZ were considered separately, there was a striking effect in HMZ (p<0.001) but not in HTZ. In exploratory analyses, significant deleterious effects were found for CIG (p=0.001), DM (p=0.03), and HTN (p=0.05) in APOE ε4 carriers only that remained significant only for CIG after correction for multiple comparisons.
CONCLUSION: CV risk factors influence age-related memory decline in APOE ε4 HMZ.
© 2011 by AAN Enterprises, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325652      PMCID: PMC3068011          DOI: 10.1212/WNL.0b013e318211c3ae

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.

Authors:  M N Haan; L Shemanski; W J Jagust; T A Manolio; L Kuller
Journal:  JAMA       Date:  1999-07-07       Impact factor: 56.272

Review 2.  Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage.

Authors:  N A Martínez-González; C L M Sudlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-08-22       Impact factor: 10.154

3.  Diabetes is related to cerebral infarction but not to AD pathology in older persons.

Authors:  Z Arvanitakis; J A Schneider; R S Wilson; Y Li; S E Arnold; Z Wang; D A Bennett
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

4.  Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center.

Authors:  Lawrence S Honig; Walter Kukull; Richard Mayeux
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

5.  The APOE polymorphism and 1-year outcome in ischemic stroke: genotype-gender interaction.

Authors:  G Gromadzka; M Baranska-Gieruszczak; I Sarzynska-Dlugosz; A Ciesielska; A Czlonkowska
Journal:  Acta Neurol Scand       Date:  2007-12       Impact factor: 3.209

6.  Long-term function in an older cohort--the cardiovascular health study all stars study.

Authors:  Anne B Newman; Alice M Arnold; Michael C Sachs; Diane G Ives; Mary Cushman; Elsa S Strotmeyer; Jingzhong Ding; Stephen B Kritchevsky; Paulo H M Chaves; Linda P Fried; John Robbins
Journal:  J Am Geriatr Soc       Date:  2009-01-29       Impact factor: 5.562

7.  Contribution of vascular risk factors to the progression in Alzheimer disease.

Authors:  Elizabeth P Helzner; José A Luchsinger; Nikolaos Scarmeas; Stephanie Cosentino; Adam M Brickman; M Maria Glymour; Yaakov Stern
Journal:  Arch Neurol       Date:  2009-03

Review 8.  Vascular cognitive impairment: current concepts and clinical developments.

Authors:  Paige Moorhouse; Kenneth Rockwood
Journal:  Lancet Neurol       Date:  2008-03       Impact factor: 44.182

9.  Apolipoprotein E genotype and response of carbon monoxide poisoning to hyperbaric oxygen treatment.

Authors:  Ramona O Hopkins; Lindell K Weaver; Karen J Valentine; Chrissa Mower; Susan Churchill; John Carlquist
Journal:  Am J Respir Crit Care Med       Date:  2007-08-16       Impact factor: 21.405

10.  Framingham Stroke Risk Profile and poor cognitive function: a population-based study.

Authors:  David J Llewellyn; Iain A Lang; Jing Xie; Felicia A Huppert; David Melzer; Kenneth M Langa
Journal:  BMC Neurol       Date:  2008-04-22       Impact factor: 2.474

View more
  36 in total

Review 1.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

2.  Sex-based memory advantages and cognitive aging: a challenge to the cognitive reserve construct?

Authors:  Richard J Caselli; Amylou C Dueck; Dona E C Locke; Leslie C Baxter; Bryan K Woodruff; Yonas E Geda
Journal:  J Int Neuropsychol Soc       Date:  2015-02-09       Impact factor: 2.892

3.  Interactive effects of apolipoprotein E4 and diabetes risk on later myelinating white matter regions in neurologically healthy older aged adults.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Tyler A Zink; Laura J Grande; Regina E McGlinchey; William P Milberg; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-12-31       Impact factor: 2.035

4.  Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons.

Authors:  Jessica B S Langbaum; Kewei Chen; Lenore J Launer; Adam S Fleisher; Wendy Lee; Xiaofen Liu; Hillary D Protas; Stephanie A Reeder; Daniel Bandy; Meixiang Yu; Richard J Caselli; Eric M Reiman
Journal:  Neurobiol Aging       Date:  2011-08-06       Impact factor: 4.673

5.  Glucose Dysregulation Interacts With APOE-∊4 to Potentiate Temporoparietal Cortical Thinning.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Regina E McGlinchey; William P Milberg; Laura J Grande; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2015-05-24       Impact factor: 2.035

6.  ApoE and pulse pressure interactively influence level and change in the aging of episodic memory: Protective effects among ε2 carriers.

Authors:  G Peggy McFall; Sandra A Wiebe; David Vergote; David Westaway; Jack Jhamandas; Lars Bäckman; Roger A Dixon
Journal:  Neuropsychology       Date:  2014-12-01       Impact factor: 3.295

Review 7.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

8.  Mid-life Cardiovascular Risk Impacts Memory Function: The Framingham Offspring Study.

Authors:  Apar Gupta; Sarah R Preis; Alexa Beiser; Sherral Devine; Lisa Hankee; Sudha Seshadri; Philip A Wolf; Rhoda Au
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Apr-Jun       Impact factor: 2.703

9.  Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study.

Authors:  Jie Shi; Natasha Leporé; Boris A Gutman; Paul M Thompson; Leslie C Baxter; Richard J Caselli; Yalin Wang
Journal:  Hum Brain Mapp       Date:  2014-01-22       Impact factor: 5.038

10.  Aberrant functional connectivity in Papez circuit correlates with memory performance in cognitively intact middle-aged APOE4 carriers.

Authors:  Wenjun Li; Piero G Antuono; Chunming Xie; Gang Chen; Jennifer L Jones; B Douglas Ward; Suraj P Singh; Malgorzata B Franczak; Joseph S Goveas; Shi-Jiang Li
Journal:  Cortex       Date:  2014-04-30       Impact factor: 4.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.